WS Investor
06 May 2026, 09:45
BioNTech Extends Losses in Premarket as COVID Revenue Decline Widens Net Loss
May 6, 2026 · Earnings Report
BioNTech shares fell 2.66% in premarket trading today, extending a 3.88% decline from the prior session, as the German biotech reported a deepening net loss in the first quarter of 2026 driven by shrinking COVID-19 vaccine revenues.
First quarter revenues came in at €118.1 million, down from €182.8 million a year ago, with net loss widening to €531.9 million from €415.8 million in Q1 2025. Diluted loss per share was €2.10 compared to €1.73 a year ago. Despite the losses, BioNTech maintained a strong cash position of €16.8 billion and announced a share repurchase program of up to $1.0 billion over the next twelve months.
Alongside the results, BioNTech announced plans to exit manufacturing sites in Idar-Oberstein, Marburg, Singapore and CureVac facilities, affecting approximately 1,860 positions. The restructuring is expected to generate around €500 million in annual recurring savings once fully implemented in 2029. The company also confirmed that co-founders Prof. Ugur Sahin and Prof. Ozlem Tureci will transition out by end of 2026 to lead a new independent mRNA company, with a successor search now underway.
On the pipeline front, five additional pivotal trials for cancer drug pumitamig were initiated during the quarter, with key data readouts expected throughout 2026. BioNTech reaffirmed its full year revenue guidance of €2.0 billion to €2.3 billion.
May 6, 2026 · Earnings Report
BioNTech shares fell 2.66% in premarket trading today, extending a 3.88% decline from the prior session, as the German biotech reported a deepening net loss in the first quarter of 2026 driven by shrinking COVID-19 vaccine revenues.
First quarter revenues came in at €118.1 million, down from €182.8 million a year ago, with net loss widening to €531.9 million from €415.8 million in Q1 2025. Diluted loss per share was €2.10 compared to €1.73 a year ago. Despite the losses, BioNTech maintained a strong cash position of €16.8 billion and announced a share repurchase program of up to $1.0 billion over the next twelve months.
Alongside the results, BioNTech announced plans to exit manufacturing sites in Idar-Oberstein, Marburg, Singapore and CureVac facilities, affecting approximately 1,860 positions. The restructuring is expected to generate around €500 million in annual recurring savings once fully implemented in 2029. The company also confirmed that co-founders Prof. Ugur Sahin and Prof. Ozlem Tureci will transition out by end of 2026 to lead a new independent mRNA company, with a successor search now underway.
On the pipeline front, five additional pivotal trials for cancer drug pumitamig were initiated during the quarter, with key data readouts expected throughout 2026. BioNTech reaffirmed its full year revenue guidance of €2.0 billion to €2.3 billion.
